OCLN

Occludin

Score: 0.513 Price: $0.51 Low Druggability Status: active Wiki: OCLN

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

415

DEBATES

3D Protein Structure

🧬 OCLN — PDB 6OWU Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Low

Score: 0.32

Clinical Stage

Approved

Target Class

Structural Protein

Safety

0.40

Druggability Analysis

Drug Development0.60

Structural Tractability0.70

Target Class0.50

Safety Profile0.40

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (3 compounds)

1 Preclinical

Therapeutic Areas:

Blood-brain barrier dysfunction Stroke and ischemic brain injury Traumatic brain injury (TBI) Neuroinflammation Neurodegenerative diseases (Alzheimer's, Parkinson's) Multiple sclerosis CNS infections and neurotropic viral diseases

Druggability Rationale: Despite its critical role in maintaining blood-brain barrier integrity, OCLN presents low druggability due to its complex transmembrane topology and limited direct binding sites for small molecule interventions. The protein's structural complexity and reliance on phosphorylation-mediated interactions suggest that therapeutic approaches may be more feasible through indirect modulators targeting upstream signaling pathways or scaffold protein interactions, rather than direct OCLN protein targeting. Current research indicates potential therapeutic strategies might involve ZO-1 modulators and tight junction scaffold protein enhancers, though these remain predominantly in preclinical stages with limited clinical validation for neurodegeneration applications.

Mechanism: Drugs targeting OCLN would stabilize or enhance tight junction protein interactions, reinforcing the structural integrity of the blood-brain barrier and reducing pathological barrier permeability. Therapeutic approaches would involve either direct protein stabilization or indirect modulation of occludin phosphorylation and trafficking to maintain barrier function.

Drug Pipeline (3 compounds)

1 Preclinical

Known Drugs:

ZO-1 modulators (research compounds) (research) — Blood-brain barrier dysfunction, neuroinflammation

Claudin-5 stabilizers (preclinical) — Stroke, traumatic brain injury, neurodegenerative diseases

Tight junction scaffold protein enhancers (research) — BBB integrity restoration in CNS disorders

Structural Data:

PDB (2) ✓AlphaFold ✓Cryo-EM —

1XAW 3G7C

UniProt: Q16625

Binding Pocket Analysis:

OCLN lacks a classical enzymatic binding pocket; structural data (PDB: 1XAW, 3G7C at 1.45 Å resolution) reveal transmembrane domains and extracellular loops as potential protein-protein interaction surfaces rather than ligand-binding sites. Therapeutic modulation likely targets allosteric regulatory regions controlling occludin phosphorylation, ZO-1 scaffold interactions, or trafficking rather than discrete binding pockets.

🧬 3D Protein Structure

🧬 OCLN — PDB 6OWU Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity challenges arise from occludin's ubiquitous expression across epithelial and endothelial barriers (BBB, intestinal epithelium, skin), creating risks for off-target barrier dysfunction in peripheral tissues. Isoform selectivity is limited as OCLN has minimal known variants, but tissue-specific delivery and BBB-penetrant formulations may provide selectivity at the anatomical level.